

# Hb Andrew-Minneapolis Variant in a Turkish Family

## Bir Türk Ailesinde Hb Andrew-Minneapolis Varyantı

© Hamza Sümter<sup>1</sup>, © Soycan Mızrak<sup>2</sup>, © Serdar Ceylaner<sup>3</sup>, © Duran Canatan<sup>4,5</sup>

<sup>1</sup>Uşak Training and Research Hospital, Clinic of Hematology, Uşak, Türkiye

<sup>2</sup>Uşak University Faculty of Medicine, Department of Biochemistry, Uşak, Türkiye

<sup>3</sup>Intergen Genetics and Rare Diseases Diagnosis Center, Ankara, Türkiye

<sup>4</sup>Antalya Genetic Assessment Center, Antalya, Türkiye

<sup>5</sup>Antalya Bilim University, Antalya, Türkiye

### To the Editor,

There are a total of 1864 known structural hemoglobin (Hb) variants [1] and Hb Andrew-Minneapolis is a rare variant. Hb Andrew-Minneapolis is a beta-chain variant of hemoglobin, which is formed with the replacement of lysine at position 144 with asparagine (HGVS name: HBB:c.435G>C, beta 144(HC1) Lys>Asn), and it was first identified in 1973 by Zak et al. [2]. This variant is inherited in an autosomal dominant manner [2,3]. The first case in Türkiye was published by Aykut et al. [4]. Here we present the Hb Andrew-Minneapolis variant in two siblings whose parents were not alive.

**Sibling 1:** A 29-year-old female patient was evaluated in our hematology outpatient clinic with polycythemia. She had no active complaints. Laboratory values were as follows: Hb: 16.5 g/dL, hematocrit (Hct): 51.7%, red blood cell count (RBC):  $8.17 \times 10^6/\mu\text{L}$ , mean corpuscular volume (MCV): 63.2 fL, mean corpuscular hemoglobin (MCH): 20.2 pg, red cell distribution width (RDW): 17.1%, white blood cell count (WBC):  $7.73 \times 10^3/\mu\text{L}$ , and platelet count (PLT):  $276 \times 10^3/\mu\text{L}$ . There were no atypical cells in the peripheral smear. Serum iron was 21  $\mu\text{g/dL}$  (normal range: 40-167), iron-binding capacity was 328  $\mu\text{g/dL}$  (normal: 70-240), serum ferritin was 5.3  $\mu\text{g/L}$  (normal: 7-277), and erythropoietin was 250 mIU/mL (normal: 4.3-29). High-performance liquid chromatography (HPLC) analysis of hemoglobin revealed HbA1 of 7.5%, HbA2 of 1.4%, HbF of 8.5%, P3 of 66.2%, and 10.2% unknown results. Although there was no diagnosis of diabetes, HbA1c was found to be high at 6.2% (normal: 3.5%-5.6%). Repeated fasting blood glucose levels were 70-80 mg/dL. Iron deficiency and abnormal hemoglobin were observed. New-generation sequencing (NGS) analysis was performed

for a definitive diagnosis and the patient was diagnosed with heterozygous Hb Andrew-Minneapolis by NGS (Figure 1).

**Sibling 2:** The 26-year-old brother of Sibling 1 was also evaluated. He had no active complaints. Laboratory values were as follows: Hb: 19.4 g/dL, Hct: 57.1%, RBC:  $6.58 \times 10^6/\mu\text{L}$ , MCV: 86.9.2 fL, MCH: 29.5 pg, RDW: 13.4%, WBC:  $7.45 \times 10^3/\mu\text{L}$ , and PLT:  $231 \times 10^3/\mu\text{L}$ . The results of HPLC analysis were as follows: HbA1: 42.2%, HbA2: 2%, HbF: 9.5%, and unknown: 46.1%. Erythropoietin was 9.49 mIU/mL (normal: 4.3-29). This patient was diagnosed with heterozygous Hb Andrew-Minneapolis by sequencing analysis. Genetic analysis of their parents could not be performed as the parents were not alive.

This is a new report of Hb Andrew-Minneapolis, detected in two siblings in Türkiye. This variant has high oxygen affinity [5]. Compared to normal HbA, however, there is less tissue oxygenation. Therefore, erythropoiesis is stimulated as compensation [6]. The oxygen pressure required for the saturation of 50% of the hemoglobin is low. The half-life for RBCs based on chromium-51 is approximately 30 days. If the HbA1c measurement conducted to evaluate the presence of diabetes mellitus in these patients is performed by HPLC, false results may be obtained, and falsely high HbA1c values are often observed [3].

Hb Andrew-Minneapolis is a rare anomaly that results in the formation of a Hb molecule with high oxygen affinity. This results in a left shift of the Hb-oxygen dissociation curve and consecutive erythrocytosis. Limited reports of falsely high HbA1c levels exist.




Figure 1. Hemoglobin Andrew-Minneapolis results by next-generation sequencing.

**Keywords:** Abnormal hemoglobins, Hemoglobin Andrew-Minneapolis, HbA1c

**Anahtar Sözcükler:** Anormal hemoglobinler, Hemoglobin Andrew-Minneapolis, HbA1c

### Ethics

**Informed Consent:** Obtained.

### Authorship Contributions

Concept- H.S.; Design- H.S., D.C.; Data Collection or Processing- H.S., S.M.; Analysis or Interpretation- D.C., S.C.; Literature Search- H.S.; Writing- H.S., D.C.

**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** The authors declared that this study received no financial support.

### References

1. <https://globin.bx.psu.edu>
2. Zak SJ, Brimhall B, Jones RT, Kaplan ME. Hemoglobin Andrew-Minneapolis  $\alpha$ A2 $\beta$ 2144Lys $\rightarrow$ Asn: a new high-oxygen-affinity mutant human hemoglobin. *Blood* 1974;44:543-549.
3. Gomi T, Ikeda T, Harano T. Hemoglobin Andrew-Minneapolis ( $\beta$ 144 (HCl) lysine  $\rightarrow$  asparagine) in a Japanese family. *Intern Med* 1992;31:659-661.
4. Aykut A, Onay H, Durmaz A, Karaca E, Vergin C, Aydınok Y, Özkinay F. Molecular analysis of abnormal hemoglobins in beta chain in Aegean region of Turkey and first reports of hemoglobin Andrew-Minneapolis and Hb Hinsdale from Turkey. *Hematology* 2015;20:354-358.
5. Khaire NS, Jamwal M, Sharma P, Hira JK, Chhabra S, Malhotra P, Das R. Hemoglobin Andrew-Minneapolis-Bijnor HBB:c.[413T>C;435G>C] in a complex genotype with  $\beta$ -thalassemia trait: a diagnostic and management conundrum. *Int J Lab Hematol* 2022;44:e164-e167.
6. Ahmed A, Jahan M, Braunitzer G, Edelbluth C, Herold W. Hb Andrew-Minneapolis [ $\beta$ 144(HC1)LYS $\rightarrow$ ASN] in a German family from Berlin. *Hemoglobin* 1989;13:189-192.



Address for Correspondence/Yazışma Adresi: Hamza Sümter, M.D., Uşak Training and Research Hospital, Clinic of Hematology, Uşak, Türkiye  
E-mail : hamzasumter@gmail.com ORCID: orcid.org/0000-0002-0224-9438

Received/Geliş tarihi: June 15, 2023  
Accepted/Kabul tarihi: July 25, 2023

DOI: 10.4274/tjh.galenos.2023.2023-0239



©Copyright 2023 by Turkish Society of Hematology Turkish Journal of Hematology, Published by Galenos Publishing House. Licensed under a Creative Commons Attribution-NonCommercial (CC BY-NC-ND) 4.0 International License.